Biopharmaceutical News and Research

RSS

Clinically-proven pharmacy product effective against causes of Traveller's Diarrhoea

It is not only overseas holidays that can be ruined by the dreaded Traveller's Diarrhoea.

23 Nov 2016

Study shows metabolite concentration can be controlled in bioreactors using OPC enabled BioProfile FLEX analyser

Current initiatives within the biopharmaceutical industry to adopt PAT (Process Analytical Technology) approaches in manufacturing, include activities in early process development.

31 Oct 2016

Wearable patch shows promise for treating children with peanut allergy

A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results from an ongoing clinical trial.

26 Oct 2016

Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics

Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson’s disease.

19 Oct 2016

Using the immune system to fight cancer: an interview with Dr Charles Akle

We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system. However, if something goes wrong with the immune system, and it no longer gets rid of these cells, then that’s when cancerous cells grow and become a problem.

12 Sep 2016

NanoTemper Technologies to highlight applications of MST, nanoDSF in drug discovery at Biopharma Workshop 2016

NanoTemper Technologies offers MicroScale Thermophoresis (MST) and nanoDSF technology to analyze these parameters in an easy and precise way. To meet the increasing demand for high-throughput applications and unattended operation, NanoTemper Technologies provides fully automated MST and nanoDSF platforms — and combinations of both.

From NanoTemper Technologies 2 Sep 2016

New collaborative initiative to develop novel ways of screening drugs for bipolar disorder, schizophrenia

The Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies will co-lead a $15.4 million effort to develop new systems for quickly screening libraries of drugs for potential effectiveness against schizophrenia and bipolar disorder, the National Institute of Mental Health (NIMH) has announced.

2 Sep 2016

TSRI scientists zoom in to view how experimental therapy ZMapp targets Ebola virus

Scientists at The Scripps Research Institute now have a high-resolution view of exactly how the experimental therapy ZMapp targets Ebola virus.

9 Aug 2016

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform.

2 Aug 2016

World's largest public-private partnership focuses on tackling antibiotic resistance

The U.S. Department of Health and Human Services, the Wellcome Trust of London, the AMR Centre of Alderley Park, Cheshire in the United Kingdom and Boston University School of Law today announced the establishment of one of the world's largest public-private partnerships focused on tackling antibiotic resistance, an emerging modern threat to public health worldwide.

29 Jul 2016

MIT researchers develop portable device to manufacture biopharmaceuticals on demand

For medics on the battlefield and doctors in remote or developing parts of the world, getting rapid access to the drugs needed to treat patients can be challenging.

29 Jul 2016

NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.

27 Jul 2016

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today.

19 Jul 2016

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis).

6 Jul 2016

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.

6 Jul 2016

Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.

6 Jul 2016

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class.

5 Jul 2016

New AAV 3.0 program to create next-generation viral vectors for better treatment of inherited diseases

The Perelman School of Medicine at the University of Pennsylvania has launched a new program, called AAV 3.0, to create new viral vectors to find quicker and better treatments for an array of diseases. James M. Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center, will lead an interdisciplinary team of over 30 scientists to create this new technology platform with support provided by the University of Pennsylvania Health System.

30 Jun 2016

Innovative RapifleX MALDI-TOF/TOF showcased by Bruker

At the 64th ASMS Conference, Bruker introducesrapifleX™, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.

From Bruker Daltonics 7 Jun 2016

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

In collaboration with Alexion Pharmaceuticals, Inc., scientists from Aarhus University have used X-rays to understand how the therapeutic antibody eculizumab prevents our immune system from destroying red blood cells and damaging kidney tissue.

6 Jun 2016

Biopharmaceutical News and Research

Clinically-proven pharmacy product effective against causes of Traveller's Diarrhoea

Study shows metabolite concentration can be controlled in bioreactors using OPC enabled BioProfile FLEX analyser

Wearable patch shows promise for treating children with peanut allergy

Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics

Using the immune system to fight cancer: an interview with Dr Charles Akle

NanoTemper Technologies to highlight applications of MST, nanoDSF in drug discovery at Biopharma Workshop 2016

New collaborative initiative to develop novel ways of screening drugs for bipolar disorder, schizophrenia

TSRI scientists zoom in to view how experimental therapy ZMapp targets Ebola virus

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

World's largest public-private partnership focuses on tackling antibiotic resistance

MIT researchers develop portable device to manufacture biopharmaceuticals on demand

NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Alnylam reports new results from investigational RNAi therapeutic programs

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Quantum Genomics initiates Phase IIa trial for heart failure

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

New AAV 3.0 program to create next-generation viral vectors for better treatment of inherited diseases

Innovative RapifleX MALDI-TOF/TOF showcased by Bruker

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News